Literature DB >> 8799511

Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications.

B K Park1, N R Kitteringham, M Pirmohamed, G T Tucker.   

Abstract

1. Human drug-metabolizing systems can be induced, or activated, by a large number of exogenous agents including drugs, alcohol, components in the diet and cigarette smoke, as well as by endogenous factors. 2. Such perturbation of enzyme activity undoubtedly contributes to both intra-and inter-individual variation both with respect to the rate and route of metabolism for a particular drug. Induction may, in theory, either attenuate the pharmacological response or exacerbate the toxicity of a particular drug, or both. 3. The clinical impact of enzyme induction will depend upon the number of different enzyme isoforms affected and the magnitude of the inductive response within an individual, and also on the therapeutic indices of the affected substrates. 4. The toxicological implications will be determined either by any change in the route of metabolism, or by a disturbance of the balance between activation and detoxication processes, which may be isozyme selective.

Entities:  

Mesh:

Year:  1996        PMID: 8799511      PMCID: PMC2042620          DOI: 10.1046/j.1365-2125.1996.03482.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs.

Authors:  L A García Rodríguez; A Duque; J Castellsague; S Pérez-Gutthann; B H Stricker
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

Review 2.  Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.

Authors:  Stig Thunell; Erik Pomp; Atle Brun
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

Review 3.  Role of variability in explaining ethanol pharmacokinetics: research and forensic applications.

Authors:  Ake Norberg; A Wayne Jones; Robert G Hahn; Johan L Gabrielsson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 4.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 5.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 6.  Systemic antifungal agents. Drug interactions of clinical significance.

Authors:  E Albengres; H Le Louët; J P Tillement
Journal:  Drug Saf       Date:  1998-02       Impact factor: 5.606

Review 7.  Long-cycle treatment with oral contraceptives.

Authors:  Inka Wiegratz; Herbert Kuhl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine.

Authors:  Yong Chen; Lisa Liu; Eric Laille; Gondi Kumar; Sekhar Surapaneni
Journal:  Cancer Chemother Pharmacol       Date:  2010-01-30       Impact factor: 3.333

Review 9.  Vitamin paradox in obesity: Deficiency or excess?

Authors:  Shi-Sheng Zhou; Da Li; Na-Na Chen; Yiming Zhou
Journal:  World J Diabetes       Date:  2015-08-25

Review 10.  Pharmacokinetic drug interactions in liver disease: An update.

Authors:  Pietro Palatini; Sara De Martin
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.